β-Amyloid (1–40) Peptide Interactions with Supported Phospholipid Membranes: A Single-Molecule Study  by Ding, Hao et al.
1500 Biophysical Journal Volume 103 October 2012 1500–1509b-Amyloid (1–40) Peptide Interactions with Supported Phospholipid
Membranes: A Single-Molecule StudyHao Ding,† Joseph A. Schauerte,† Duncan G. Steel,†§ and Ari Gafni†‡*
†Department of Biophysics, ‡Department of Biological Chemistry, and §Department of Physics, University of Michigan, Ann Arbor, MichiganABSTRACT Recent evidence supports the hypothesis that the oligomers formed by the b-amyloid peptide early in its
aggregation process are neurotoxic and may feature in Alzheimer’s disease. Although the mechanism underlying this neurotox-
icity remains unclear, interactions of these oligomers with neuronal membranes are believed to be involved. Identifying the
neurotoxic species is challenging because b-amyloid peptides form oligomers at very low physiological concentrations (nM),
and these oligomers are highly heterogeneous and metastable. Here, we report the use of single-molecule imaging techniques
to study the interactions between b-amyloid (1–40) peptides and supported synthetic model anionic lipid membranes. The evolu-
tion of the b-amyloid species on the membranes was monitored for up to several days, and the results indicate an initial tight,
uniform, binding of b-amyloid (1–40) peptides to the lipid membranes, followed by oligomer formation in the membrane. At these
low concentrations, the behavior at early times during the formation of small oligomers is interpreted qualitatively in terms of the
two-state model proposed by H. W. Huang for the interaction between amphipathic peptides and membranes. However, the rate
of oligomer formation in the membrane and their size are highly dependent on the concentrations of b-amyloid (1–40) peptides in
aqueous solution, suggesting two different pathways of oligomer formation, which lead to drastically different species in the
membrane and a departure from the two-state model as the concentration increases.INTRODUCTIONThe formation of senile plaques in brain tissue is a hallmark
of Alzheimer’s disease (AD) (1–3). It has been found that
b-amyloid peptides, which are 39–43 amino acid residues
in length, are the major component of the plaques (4–6)
and are able to self-assemble into highly ordered fibrillar
structures in aqueous solution (7,8). There is evidence that
b-amyloid (1–40) peptide is more concentrated in the cere-
brovascular plaques, whereas b-amyloid (1–42) peptide is
more abundant in the neuritic plaques (9). Historical
research shows that the composition of b-amyloid deposits
in AD brains can also vary considerably from patient to
patient (10–12).
The presence of b-amyloid fibrils in brains of AD patients
has led to the amyloid hypothesis, which proposed that these
fibrils are toxic to neuronal cells and are a causative factor in
AD (13,14). However, recent experimental evidence has
indicated that early b-amyloid oligomers, rather than the
mature fibrils, are likely the neurotoxic species (15–20).
Indeed, there is evidence that b-amyloid oligomers, as small
as dimers, are capable of disrupting synaptic plasticity and
memory (19,20). One hypothesis to explain the neurotox-
icity of the b-amyloid oligomers is that these peptide aggre-
gates form ion-conducting pores in neuronal membranes,
and that the resulting imbalance of calcium ions across the
membranes can either lead to direct cell death or trigger
the signaling for apoptosis (21). Small oligomeric struc-
tures, which consist of a minimum of 4~6 monomeric units,Submitted February 11, 2012, and accepted for publication August 29,
2012.
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0006-3495/12/10/1500/10 $2.00are likely involved in the formation of membrane pores
(17,22). Moreover, anionic membranes have been found to
be especially prone to the pore formation process (23–28),
although a few studies have reached contradictory con-
clusions (29–31). Some recent studies have also suggested
other possible mechanisms for b-amyloid-induced calcium
permeability, such as by b-amyloid peptide interacting
with GM1 ganglioside (32), or by b-amyloid oligomers
affecting glutamatergic receptors (33,34).
Despite the growing attention to early b-amyloid oligo-
mers, the study of these potentially pore-forming species
has proved challenging, because they are heterogeneous,
dynamic, and exist at extremely low concentrations in the
brain. It has been suggested that the lack of a clear descrip-
tion of the toxic b-amyloid oligomer has hindered our
understanding and interpretation of the controversial results
in Alzheimer’s research (35,36). Single-molecule tech-
niques have been shown to be very promising tools for
studying these small oligomeric structures, because indi-
vidual b-amyloid oligomers can be detected and identified
at very low peptide concentrations.
In this work, we used single-molecule imaging tech-
niques to study the interactions between b-amyloid (1–40)
and a supported anionic lipid membrane to gain deeper
understanding of the mechanism of b-amyloid neurotox-
icity. In our experiments, the evolution of b-amyloid species
in anionic lipid membranes was monitored for up to several
days. The results indicate an initial tight, uniform, binding
of b-amyloid (1–40) peptide to the lipid membrane, fol-
lowed by oligomer formation in the membrane. This result
is qualitatively compared to the two-state model proposed
for peptide membrane interactions (37,38). The results ofhttp://dx.doi.org/10.1016/j.bpj.2012.08.051
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two different pathways of oligomer formation in the
membrane, both yielding a wide range of oligomer species.
A significant fraction of the oligomers formed via one of
these pathways is composed of smaller species, which
have also been observed by high-resolution atomic force
microscopy imaging in previous studies (17,22).MATERIALS AND METHODS
b-amyloid (1–40) preparation
The HiLyte Fluor 488 b-amyloid (1–40) (AnaSpec, San Jose, CA) was
stored frozen at 20C. The peptide was dissolved in 2% ammonium
hydroxide (J. T. Baker, Phillipsburg, NJ) at 1 mg/ml, and then aliquotted
into small samples, lyophilized, and stored at 20C. To make a fresh
b-amyloid (1–40) solution, the lyophilized powder was directly dissolved
into 10 mM sodium phosphate, 100 mM sodium chloride, pH7.4 buffer.
The same buffer was used in all the experiments conducted in this work.
In addition, only freshly dissolved b-amyloid (1–40) peptide was used, at
a concentration of 100 nM, and these samples contain ~70% monomers
as shown by single-molecule measurements. Because the oligomers exist
in a dynamic equilibrium with monomeric peptide and oligomerization is
a high order reaction and hence highly concentration dependent, it appears
highly plausible that at lower peptide concentrations as used in out exper-
iments, i.e., 2 nM, the oligomeric fraction is markedly lower and the peptide
is very predominantly monomeric.Total internal reflection fluorescence microscopy
Fluorescence emission from HiLyte Fluor 488 b-amyloid (1–40) peptide
was collected by a custom-made inverted total internal reflection fluores-
cence (TIRF) microscope (39–41). Both b-amyloid peptide and lipid
membrane were imaged in the salient environment (10 mM sodium phos-
phate, 100 mM sodium chloride, pH7.4), and at room temperature
(22C). The microscope was equipped with a 1.45NA 60X oil-immersion
objective (Olympus, Center Valley, PA). An Arþ-ion laser (I-90, Coherent,
Santa Clara, CA) operating at 488.0 nm was used as the excitation source
and delivered a laser power of 500 mW at the sample plane. The fluores-
cence signal was filtered by a 520/60 nm band-pass filter (Chroma,
Rockingham, VT), and recorded by an electron-multiplying CCD camera
(Andor, South Windsor, CT) with an exposure time of 50 ms/frame. Due
to the evanescent wave in the TIRF geometry, only fluorophores that are
very close to the glass/water interface (~150nm) are excited and detected.Supported anionic lipid membrane preparation
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, molecular
weight 760.08) and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-
glycerol)] (POPG,molecular weight 770.99) (both fromAvanti Polar Lipids,
Alabaster, AL) were stored at20C. In all of our experiments, a mixture of
POPC (neutral/zwitterionic) and POPG (negative) with a molar ratio of 1:1
was used to form the supported anionic membranes on coverglasses (Fisher
Scientific, Pittsburgh, PA) that had been precleaned with MilliQ (Millipore,
Billerica, MA) water rinsing followed by kiln baking at ~500C for 2 h.
To form an anionic lipid membrane on the coverglass, small unilamellar
vesicles (SUVs) were first made (42,43). 0.5 mg POPC and 0.5 mg POPG
were codissolved in chloroform, and then dried under gaseous nitrogen in
a fume hood (a molar ratio of 1:1 was achieved due to the close molecular
weight of POPC and POPG). A further removal of residual chloroform was
achieved by vacuum drying of the sample overnight. Before the preparation
of SUVs, the dried lipids were hydrated in buffer (10 mM sodium phos-phate, 100 mM sodium chloride, pH 7.4) for 2 h at room temperature,
during which the sample was vortexed a few times to completely resuspend
the lipids. SUVs were then formed by sonication of the lipid suspension in
an ice water bath for 2–5 min until the suspension became clear. Finally, the
supported lipid membranes were spontaneously assembled by incubating
the freshly prepared SUVs on a clean coverglass surface overnight (43).
After the formation of the supported lipid membrane, the unbound SUVs
were gently washed off with buffer. 100% surface coverage of the supported
bilayer was confirmed under the microscope.Application of fluorescence recovery after
photobleaching (FRAP) to determine membrane
fluidity
FRAP experiments were used to measure the mobility of the lipid mole-
cules and the membrane-bound b-amyloid (1–40) peptide (44,45). It should
be noted that, for measuring the mobility of lipid molecules, 0.5% nitro-2-
1,3-benzoxadiazol-4-yl-POPC (NBD-POPC; Avanti Polar Lipids) was
mixed with POPC and POPG to allow fluorescence photobleaching and
recovery. In a typical FRAP experiment, a circular area of membrane of
~45 mm in diameter was photobleached by high intensity laser illumination
for a short duration (5 s). (Because the laser intensity is higher than the
saturation level of the dye molecules, the uneven illumination still yielded
a relatively flat photobleaching profile, which satisfies the assumption in
using the following analysis method for extracting diffusion coefficient.)
The fluorescence recovery in the photobleached region was then recorded
using much weaker illumination intensity (<1/2500 of the photobleaching
intensity). Because all the free lipid molecules (or b-amyloid (1–40)
peptide) in solution had been washed off extensively, the fluorescence
recovery was purely due to the lateral diffusion of the lipid molecules (or
the membrane-bound b-amyloid (1–40) peptide) in the membrane. This
mobility measurement of the lipid molecules was also used to confirm
the integrity of the lipid membranes.
To extract diffusion coefficients from FRAP experiments, the fluores-
cence recovery curves were fit to the following equation (45) using
Mathematica: f ðtÞ ¼ expð2tD=tÞ½I0ð2tD=tÞ þ I1ð2tD=tÞ. In this equa-
tion, f ðtÞ is the integrated fluorescence intensity over the photobleached
region: I0 and I1 are the modified Bessel functions of the first kind
ðInðzÞ ¼ 1=2 pi #eðz=2Þðtþ1=tÞtn1dtÞ. And tD ¼ w2=4D is the characteristic
diffusion time, with w being the radius of the photobleached region, and D
being the diffusion coefficient.b-amyloid (1–40) interaction with lipid membrane
After POPC/POPG lipid membrane was formed on clean coverglass
substrate, freshly prepared HiLyte Fluor 488 b-amyloid (1–40) peptide
was added to the desired concentration by gentle pipetting. The sample
holder was then sealed with parafilm to prevent evaporation of the solution.
The incubation of b-amyloid (1–40) peptide with lipid membrane was kept
at room temperature (22C).RESULTS
It was critical to confirm that the fluorescence labeling of
b-amyloid with HiLyte Fluor 488 did not alter the properties
of the peptide. NMR studies of b-amyloid peptides structure
indicate that the N-terminus of the peptide, where the
fluorophore is attached, is flexible, suggesting the peptides
should be minimally perturbed by the labeling (8). Mem-
brane conductivity experiments indeed confirmed that both
labeled and unlabeled b-amyloid (1–40) peptides per-
meabilize lipid membranes with similar efficiency (46). InBiophysical Journal 103(7) 1500–1509
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that both labeled and unlabeled peptides form fibrillar struc-
tures with almost identical morphologies (47).
To study b-amyloid (1–40) peptide interactions with lipid
membranes, supported anionic membranes were formed on
clean coverglass. HiLyte Fluor 488 b-amyloid (1–40)
peptide solution was added and a TIRF microscope was
used to monitor the interactions between the peptide and
the membrane. Depending on the concentration of the added
b-amyloid (1–40), the peptide-membrane interactions were
monitored for a period of a few hours, with high peptide
concentration, ~100 nM, to over 6 days, with low peptide
concentration, ~2 nM.
The results of these experiments reveal that the interac-
tions between the peptide and membrane can be divided
into two stages where an initial tight and uniform binding
of b-amyloid (1–40) peptide to the anionic membrane
is followed by the formation of membrane-embedded
b-amyloid (1–40) oligomers.FIGURE 1 (a) TIRF image of background fluorescence (taken with sup-
ported POPC/POPG lipid membrane only). (b) TIRF image of HiLyte Fluor
488 b-amyloid (1–40) peptide bound to POPC/POPG lipid membrane.
The concentration of b-amyloid (1–40) peptide in solution is 100 nM. (c)
The kinetics of the same concentration of b-amyloid (1–40) peptide binding
to the membrane. The data could be fit to a single exponential very well,
indicating a first-order binding kinetics.Uniform binding
Following the addition of freshly dissolved HiLyte Fluor
488 b-amyloid (1–40) to the anionic membrane, a uniform
binding of the peptide to the membrane took place, as re-
vealed by an elevated and featureless fluorescence across
the entire field of view of ~120 mm in diameter (see Fig. 1
b, and for comparison, a background image with supported
membrane only is shown in Fig. 1 a. The variation in the
intensity across the field in both images corresponds to the
TIRF illumination gradient). The duration of the uniform
binding phase (i.e., before discrete structures develop)
ranged from <2 h (for high peptide concentration in solu-
tion, ~100 nM) to a few days (for low peptide concentration
in solution, ~2 nM).
Binding kinetics
The initial, uniform, binding of the peptide to the membrane
was found to be slow, as indicated by the slow increase
in the observed mean fluorescence intensity from the
membrane-bound b-amyloid (1–40) (Fig. 1 c). This binding
is well fit by a single exponential, suggesting the process
obeys first-order kinetics.
The following model is proposed for the binding process:
½MembraneBindingSites þ ½SolutionAb4kon
koff
½MembraneBoundAb:
We can further simplify this model based on the following
two observations made in our experiments.
1. koff is extremely small. In our experiments, after the
aqueous phase containing unbound b-amyloid (1–40)
was washed off extensively and replaced by peptide-freeBiophysical Journal 103(7) 1500–1509buffer, the fluorescence intensity of the membrane-bound
peptide did not noticeably decrease even after 130 h. This
sets the upper limit of koff at below 2  106s1.
2. b-amyloid (1–40) saturates the membrane at very
low peptide/phospholipid ratios. Crude measures of
b-amyloid (1–40) concentration, via the fluorescence
intensity from the solution, were done both before and
after the peptide bound to the membrane. No measurable
decrease was detected; indicating the majority of the
peptide remained in solution. Furthermore, a higher
concentration of solution peptide up to 100 nM did not
increase the binding of b-amyloid (1–40) to the
membrane, as indicated by the lack of change in the fluo-
rescence intensity from the membrane-bound peptide
regardless of aqueous peptide concentration between 2
and 100 nM. These observations suggest that the fraction
of peptide that bound to the membrane was extremely
small ([Solution Ab] z [Solution Ab]0 >> [Membrane
Bound Ab]). A more direct estimate of the bound peptide,
based on the density of the membrane-bound b-amyloid
(1–40) peptide confirms this conclusion and is provided
in the Discussion.
Combining the previous two observations, the binding of
b-amyloid (1–40) to the lipid membrane can be presented as
a simplified irreversible process:
FIGURE 2 FRAP of a POPC/POPG lipid bilayer. The bilayer was
mixed with 0.5% NBD-POPC for fluorescence photobleaching and
recovery. Snapshot images at 0 s, 20 s, 50 s, and 300 s are shown in
a–d. (e) The fluorescence recovery curve was fit to the equation
f ðtÞ ¼ expð2tD=tÞ½I0ð2tD=tÞ þ I1ð2tD=tÞ to extract the diffusion
coefficient.
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kon
½MembraneBoundAb:
Therefore, the binding process shown in Fig. 1 c is de-
scribed by a single exponential curve A1(1-exp(kon[Added
Ab]  t)) þ A2 (A1 represents the fluorescence intensity
when the membrane-bound b-amyloid peptide saturates,
and A2 is the fluorescence baseline; i.e., autofluorescence
from the membrane). kon¼ (4.3 5 0.4)  103 s1M1
was derived from the curve fitting. Various concentrations
(20, 50, and 100 nM) of b-amyloid (1–40) were tested,
and a consistent kon was found. Data from 100 nM peptide
are shown in Fig. 1 c, and data from other concentrations
can be found in Fig. S1 in the Supporting Material. With
the estimated upper limit for koff (<2  106s1), an upper
limit for the dissociation constant of the peptide from the
membrane can be calculated: Kd ¼ koff /kon <470 pM.
This extremely low Kd reveals a very tight binding of
b-amyloid (1–40) to the anionic membrane, albeit saturating
at a very low peptide/lipid ratio. This Kd is much lower than
the value reported in our previous study (23) in that the
previous Kd was determined at much higher peptide con-
centrations (micromolar) where a second binding process
involving a much higher peptide/lipid ratio occurs, which
is very different from the tight binding at subnanomolar
peptide concentrations reported in the current study.
The membrane-bound b-amyloid (1–40) is very mobile
The mobility of lipid molecules as well as of the membrane-
bound b-amyloid (1–40) peptide in the membrane was mea-
sured by FRAP. A circular region in the membrane was
photobleached, and the fluorescence recovery via lateral
diffusion was then recorded. Fig. 2, a–d, show four typical
FRAP images. To measure the mobility of the lipid mole-
cules, the membrane was made using lipids containing
0.5% NBD-POPC thereby allowing for fluorescence imag-
ing. The diffusion coefficient was derived by fitting of
the recovery curve to the model described in Methods.
Fig. 2 e shows the recovery curve of the membrane-bound
b-amyloid (1–40) peptide and the corresponding curve
fitting.
FRAP measurements of the lipid molecules and the
membrane-bound b-amyloid (1–40) peptide yielded com-
parable diffusion coefficients: 1.6 5 0.1 108cm2/s and
2.3 5 0.2 108cm2/s, respectively. This shows that the
membrane-bound b-amyloid (1–40) is very mobile, with
a diffusion coefficient similar to that of the lipid molecules.Oligomer formation
Fig. 3 a shows the membrane after incubation with 2 nM
of b-amyloid (1–40) peptide for 20 h and then washed off
showing no oligomer formation. Prolonged incubation of
the membrane-bound peptide led to slow oligomer forma-tion (Fig. 3, b–d). These oligomers appeared as bright spots
in the fluorescence images. Inspection of these images re-
vealed that the uniformly bound peptide remained attached
to the membrane during oligomer formation, as indicated by
the presence of elevated fluorescence backgrounds in all the
images. Contrary to the uniformly bound peptide, which
showed good mobility in the membrane, the oligomers
appeared to be immobilized based on time lapse observation
up to 30 min.
Peptide concentration dependence of oligomer formation
Our experiments reveal that the rate of formation of
membrane-bound oligomers depends on the concentration
of the b-amyloid (1–40) peptide in solution. Experiments
using three peptide concentrations (0, 2, and 100 nM in solu-
tion) suggested that oligomer formation most likely occurs
via two different mechanisms. It should be noted that prein-
cubation of the lipid membrane with b-amyloid (1–40) was
performed in all the experiments, as oligomer formation wasBiophysical Journal 103(7) 1500–1509
FIGURE 3 (a) Fluorescence image of the membrane-bound b-amyloid
(1–40) peptide, after incubation with 2 nM of b-amyloid (1–40) peptide
for 20 h and then washed off, before oligomers formation was observed.
(b–d) Fluorescence images showing oligomer formations in the membrane
with different concentrations of b-amyloid (1–40) peptide in solution:
(b) oligomers formed with 0 nM b-amyloid (1–40) peptides in solution
for 130 h; (c) oligomers formed with 2 nM b-amyloid (1–40) peptides in
solution for 130 h; (d) oligomers formed with 100 nM b-amyloid (1–40)
peptides in solution for 3 h.
1504 Ding et al.observed to occur only after a uniform binding of the
peptide to the membrane (even for the 0 nM experiments,
2 nM of peptide was incubated with lipid membranes
for 20 h before the peptide was washed off extensively,
Fig. 3 a).
Oligomer formation with peptide-free solution. When the
solution b-amyloid (1–40) was washed off (after 20 h incu-
bation with the membrane), the imaging of the membranes
after 130 h revealed the presence of oligomers (Fig. 3 b).
There were 34 5 4.4 oligomers observed per field of view
after the 130 h incubation (error bar calculation based on
10 fields of view, and each field of view is ~120 mm in
diameter).
Because there was no b-amyloid (1–40) available in solu-
tion, these oligomers clearly formed within (or on) the
membrane from b-amyloid (1–40) peptide that was bound
to the membrane during the preincubation.
Oligomer formation with low concentration (2 nM) of
peptide in solution. When the preincubated membrane
with 2 nM b-amyloid (1–40) peptide in solution was fol-
lowed for 130 h, the oligomer formation (see in Fig. 3 c)
was very similar to that seen in the absence of solution
peptide (Fig. 3 b). The observed number of oligomers per
field of view was 415 6.9 in this case, only slightly higher
than that observed with no peptide in solution (error barBiophysical Journal 103(7) 1500–1509calculation based on nine fields of view). The fluorescence
intensities of the oligomers in both experiments were very
similar as well, suggesting similar sizes as discussed in
more detail below. We conclude that although the excess
free b-amyloid (1–40) in solution can serve as a reservoir
for oligomer formation, the oligomerization under these
conditions is still mainly due to membrane-bound peptide
in a similar mechanism to that of oligomer formation in
the absence of solution peptide.
Oligomer formation with high concentration (100 nM)
of peptide in solution. Monitoring the membrane with
100 nM b-amyloid (1–40) in solution for only 2.5 h revealed
a dramatically increased level of oligomer formation
(Fig. 3 d). Though the incubation time was much shorter,
the density and the fluorescence intensities of the oligomers
formed in the membrane were much higher than those in the
previous two experiments. 1325 17 oligomers per field of
view were observed after the short incubation (error bar
calculation based on eight fields of view). It should be noted
that, the gain of the electron-multiplying CCD camera was
lowered in these experiments, which accounts for the darker
background seen in Fig. 3 d. This much faster oligomer
formation suggests that these oligomers were likely formed
via a different mechanism.
Comparison of oligomer species
Although fluorescence intensities of individual membrane-
bound oligomers can be used to assess their sizes, the illumi-
nation gradient caused by both the Gaussian profile of the
laser beam and the TIRF geometry makes the absolute in-
tensities of the oligomers’ fluorescence a poor measure of
their sizes. Thus, normalized fluorescence intensities were
used to compare the different oligomer species.
As had been observed in the experiments, the uniformly
bound b-amyloid (1–40) remained associated with the
membrane during oligomer formation appearing as an
elevated background. This background could be served as
a reference for the normalization of the oligomer fluores-
cence intensities. Based on the rationale that smaller
regions, such as 9  9 pixels in our images, are more likely
to have approximately uniform illumination, the fluores-
cence intensity of a single pixel can be normalized to its
averaged local background. Consequently, an oligomer
can be represented as the integration of the normalized pixel
intensities within its diffraction-limited area, giving a more
accurate estimate of oligomer size. Thus, in the postnormal-
ized images, the background regions that represent the
mobile, uniformly bound peptide have normalized intensi-
ties of around unity, whereas the oligomers have normalized
intensities well above unity.
By normalizing the fluorescence intensities, the oligo-
meric species in a given experiment can be compared.
Moreover, based on our finding that the saturation level of
membrane-bound b-amyloid (1–40) is the same regardless
of peptide concentration in solution, the sizes of the
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through normalization. The background fluorescence in
Fig. 3, c and d, showed very similar intensities, though
Fig. 3 d appears to be darker due to different contrast and
gain settings. Applying this approach we found that at low
concentration of solution peptide only small oligomers
were formed, with normalized intensities <12 (as shown
in Fig. 4 a, which depicts the data of Fig. 3 c in normalized
fluorescence intensities). In contrast, in the presence of
a high concentration of solution peptide, much larger
oligomers were formed, as indicated by much higher (up
to around 100) normalized intensities (shown in Fig. 4 b,
which presents the data of Fig. 3 d in normalized fluores-
cence intensities).
Determination of oligomer species
We showed that the oligomer species are correlated with
their normalized fluorescence intensities. However, this
normalization did not give a real estimation of oligomer
size. On the other hand, single molecule photobleaching
has been used to determine in a direct way the number of
subunits in molecular assemblies (48,49). By counting the
number of steps in photobleaching trajectories, the sizes
of spin-coated b-amyloid (1–40) oligomers have been
unambiguously determined (47).FIGURE 4 Comparison of the b-amyloid (1–40) oligomers formed at
low concentration (2 nM) in a and c, and high concentration (100 nM)
in b and d. In a and b, three-dimensional images of oligomers in the
membranes are presented, with z axis indicating the normalized fluores-
cence intensity, and x and y axes representing the pixel numbers of the
image. Please see the text for detailed explanation of normalized fluores-
cence intensity. In c and d, histograms of b-amyloid (1–40) oligomers are
compared in oligomeric units. It should be noted that, a significant fraction
(34.0%) of the oligomers formed at low peptide concentration, as high-
lighted in c, are smaller species (trimers/tetramers).We note that the usual photobleaching methodology
(47–49) did not yield clear results in the current study due
to the presence of mobile b-amyloid (1–40) peptide that
contributes to the photobleaching trajectory. However, the
individual photobleaching events that can often be identified
in the trajectories provided an accurate means of estimating
the size of monomeric units of b-amyloid peptide, because
a discrete photobleaching step corresponds to the loss of
fluorescence from a single b-amyloid peptide molecule
(a selection of photobleaching events can be found in
Fig. S2, a–f). By comparing the photobleaching fluores-
cence loss with its local background, we can further cali-
brate the normalized fluorescence intensities. With the
background fluorescence being represented as unity in the
normalization process, the ratio of background fluorescence
over photobleaching loss yields the number of monomeric
b-amyloid units per normalized fluorescence unity. A total
of 121 single-step photobleaching events were selected,
and an average of 2.5 5 0.9 monomeric units per normal-
ized fluorescence unit was calculated from the calibration
(distribution of monomeric units/normalized fluorescence
unit from the selected photobleaching events can be found
in Fig. S2 g).
Based on the calibration of the normalized fluorescence
unit, the oligomer sizes could be determined with a reason-
able degree of confidence (oligomer size ¼ normalized
intensity 2.5). Fig. 4, c and d, show the histograms of olig-
omeric species formed under different experimental condi-
tions: low b-amyloid peptide concentration (2 nM) in
solution in (c), and high peptide concentration (100 nM)
in (d). The comparison of the histograms not only shows
a large difference in size between the oligomers formed at
different peptide concentrations, but also indicates that
even under the same experimental condition; there is a large
variation in the oligomeric species. Furthermore, among the
oligomers formed at low peptide concentration, a significant
fraction (34.0%) contains smaller species, as highlighted in
Fig. 4 c. These smaller species are estimated to be mainly
trimers and tetramers. In fact, high-resolution atomic force
microscopy imaging has also revealed similar small olig-
omer species in membranes (17,22). These species may be
the smallest stable oligomers in the membrane and, there-
fore, could be the origin of pore formation and neurotox-
icity. It should be noted that, due to possible fluorophore
self-quenching, the sizes of these oligomers may be under-
estimated, especially for the large species. However, we also
note that for HiLyte Fluor 488 b-amyloid (1–40) oligomers
sizes up to 20, self-quenching as determined by fluorescence
lifetime was not observed.DISCUSSION
Though there is extensive evidence to support the role of
membrane-associated b-amyloid oligomers in AD, the
molecular mechanism by which these structures form andBiophysical Journal 103(7) 1500–1509
1506 Ding et al.the origin of their neurotoxicity remain poorly understood
(15–20). More detailed studies of peptide membrane
interactions are therefore critical for understanding the
underlying mechanisms. Because b-amyloid peptides are
found in extremely low physiological concentration and
can form heterogeneous and dynamic oligomeric species,
these mechanistic studies are challenging for traditional
techniques. In our research, single-molecule fluorescence
imaging techniques are used to study the peptide membrane
interactions.
Our results show that the initial interactions between
b-amyloid (1–40) and anionic membranes lead to a very
tight and uniform binding of the peptide to the membrane
(Fig. 1 b), but at a very low peptide/lipid ratio, followed
by the slow formation of a variety of oligomer species in
the membrane (Fig. 3, b–d).A two-state model for peptide membrane
interaction
A two-state model has been proposed in the literature
for peptide membrane interaction (37,38). Though origi-
nally developed specifically for antimicrobial peptides, the
model is general and applicable for other peptide membrane
interactions.
In this model, membrane-bound peptides exist in two
different states: the membrane-bound monomeric state and
the oligomeric state. It has been shown that these two states
are directly related to the peptide/lipid ratio, which can be
defined as the number of membrane-bound peptide over
the number of lipid molecules. At low peptide/lipid ratio,
the membrane-bound peptide is in the monomeric state,
and is at the interface between the hydrophilic headgroups
and hydrophobic regions of the lipid, with an orienta-
tion parallel to the membrane surface (37,38). When the
peptide/lipid ratio is above the threshold value, the peptide
oligomerizes in the membrane and assumes a perpendicular
orientation relative to the membrane surface.
Though the long timescales and decreasing signal/noise
did not allow us to identify the threshold value for the
peptide/lipid ratio (<105), our results for b-amyloid
(1–40) interacting with anionic membranes show behavior
that at low concentrations is generally compatible with the
previous model. During the initial incubation of b-amyloid
with the membrane, where earlier studies have shown
b-amyloid assumes a a-helical structure (46), saturation
occurs at a very low peptide/lipid ratio but with very high
affinity and all the membrane-bound peptide is highly
mobile and uniformly distributed in the membrane. Further
incubation of the membrane-bound b-amyloid (1–40) leads
to the appearance of oligomers in the membrane. The immo-
bility of these oligomers indicates that their constituent
peptides are inserted into the membrane. This transition
from a mobile monomeric state to an immobile oligomeric
one is in accordance with the two-state model. Other studiesBiophysical Journal 103(7) 1500–1509of molecular tracking show that the largest mobile species is
a dimer (C. Chang, D. G. Steel, and A. Gafni, unpublished).
In addition, our previous study using circular dichroism (46)
has revealed that the small membrane-bound peptide oligo-
mers adopt a mostly helical structure, whereas as larger olig-
omers develop there is a shift to beta-structure, which can
also be evidenced by thioflavin T binding. Previous NMR
studies of b-amyloid (1–40) in micellar environment have
also shown that the peptide’s C-terminus adopts a helical
structure, with the length of the peptide (~4 nm) spanning
the membrane (50). This is comparable with the thickness
of a lipid bilayer. Therefore, these perpendicularly oriented
oligomers are likely to be anchored by the underlying glass
substrate, explaining their immobility. As we discuss below,
at higher concentration, our results deviate considerably
from this model.Membrane-bound b-amyloid (1–40) peptide
Our results show that during the initial, uniform, binding
phase of b-amyloid (1–40), the fraction of the solution-
peptide that binds to the membrane is small, and that mem-
brane saturation occurs at an extremely low peptide/lipid
ratio (below 105, see discussion below). Because the mem-
brane-bound b-amyloid (1–40) peptide is mobile and evenly
distributed, they appear as elevated fluorescence back-
grounds in the images (Fig. 1 b). The data show (see
Results) that they remain attached to the membrane during
oligomer formation.
This elevated fluorescence background has a normalized
fluorescence intensity of unity, which suggests the density
of the membrane-bound b-amyloid (1–40) peptide to be
2.5 5 0.9 monomeric units per pixel, or 8.8 5 3.2 mono-
meric units/mm2 via the calibration of the normalized fluo-
rescence. The average surface area of a lipid molecule in
the membrane is ~70A˚2 (51,52), making for ~1.43  106
lipid molecules/mm2. This reveals that b-amyloid (1–40)
membrane concentration at saturation is extremely low,
with peptide/lipid ratio of ~105106. This low ratio
supports our experimental observation that the fraction of
solution b-amyloid (1–40) that binds to the membrane is
extremely small. Thus, it can be calculated from this low
peptide/lipid ratio that, even with 2 nM peptide in solution,
the majority of the peptide (99.8%) was still in solution after
the membrane binding sites were saturated.
High affinity binding of b-amyloid (1–40) peptide to
black lipid membranes, with similar peptide density, has
been observed (46). Murphy et. al. (53) have also reported
a similar binding of b-amyloid (1–40) peptide to lipid vesi-
cles using surface plasmon resonance. Isothermal titration
calorimetry experiments conducted in our group also sug-
gest a very tight binding of the peptide to the membrane
at low peptide/lipid ratio conditions (data not shown).
Clearly, this extremely tight and yet extremely low density
binding of the peptide to the membrane is puzzling and
Single Molecule Ab Membrane Interaction 1507a satisfactory molecular mechanism to explain it remains to
be developed. It should be noted that selective b-amyloid
binding to contaminants or impurities in the lipid is unlikely
to explain the tight binding, because similar peptide binding
densities have been observed on different model membranes
with various lipid compositions (46,53).Pathways of oligomer formation
It was shown under Results that oligomer formation in the
membrane did not start until well after a uniform binding
of b-amyloid (1–40) peptide to the anionic membrane
took place. The concentration-dependent rate of oligomer
formation suggests there are likely two different pathways
for this process.
Upon washing off solution b-amyloid (1–40), oligomer
formation in the membrane was still observed, albeit slowly.
This indicates the membrane-bound peptide undergoes
a transition from the monomeric state to the oligomeric
state. It was also shown in Results that, with low peptide
concentration in solution, the in-membrane transition path-
way still dominates oligomer formation.
On the basis of the peptide surface density and the diffusion
coefficient of the membrane-bound mobile peptide
(assuming it to be monomeric), we calculated the collision
frequency of the mobile peptide in the membrane using the
equation F ¼ 4pC2D=ln½ðpCÞ1=2=a (54,55), where F is
the collision frequency per unit area, C is the density of the
peptide (8.8  108/cm2), D is the two-dimensional diffusion
coefficient (2.3  108cm2/s), and a is the collision radius,
which can be approximated as the cross-section diameter of
b-amyloid (1–40) oligomers. From the sizes of the oligomeric
pore reported in the literature (17,22), a is on the order of ten
nanometers. This calculation yields ~71010 collisions/
cm2/s for the monomeric peptide diffusing in the membrane,
giving ~90 collisions/s for each monomer. It is thus clear that
the pathway leading to oligomer formation by membrane-
bound peptide is far from a diffusion-controlled process,
because the collision frequency between the mobile peptide
molecules is much higher than the number of oligomers
observed on our measurement of (0.7 oligomers/cm2/s). It
is possible that the oligomerization of the membrane-bound
peptide may require some specific orientations or more
subunits during peptide collision in the membrane. It is also
possible that the actual collision frequency of membrane-
bound peptide is much less than the previous estimate. The
two-state model suggests that the membrane will undergo
a local thinning/deformation upon peptide adsorption.
Because the local membrane thinning/deformation is repul-
sive due to a high energy cost for overlapping these areas,
this may create barriers around the membrane-bound peptide
molecules, and prevent them fromcollidingwith eachother to
form stable oligomers (37,38).
In the presence of a high peptide concentration in
solution, however, the rate of oligomer formation in themembrane was found to be much higher. Because the
surface density of the membrane-bound mobile peptide
was the same for both high and low peptide concentrations
in solution (in Fig. 3, c and d), the rate of oligomer forma-
tion via the membrane-peptide transition pathway has to be
the same as well. This suggests that oligomer formation on
the membrane via bound peptide diffusion cannot account
for the much faster oligomer formation seen at high solution
peptide. Clearly, a second pathway of oligomer formation
has to exist, which likely involves either a direct insertion
of solution peptide into a membrane-bound preexisting
oligomer, or a rapid replenishing of membrane-bound
monomeric peptides that have been incorporated into oligo-
meric species. Indeed, oligomer formation at a low solution
peptide concentration of 2 nM did not show any contribution
from the direct insertion pathway, although the latter path-
way dominated at 100 nM solution peptide. The fast form-
ing oligomers may further serve as nuclei for subsequent
binding of b-amyloid peptide to the membrane, leading to
more severe membrane permeabilization, or even initiating
b-amyloid fibril formation. Indeed, mesh-like b-amyloid
deposits were observed after prolonged incubation of
100 nM b-amyloid (1–40) peptide with POPC/POPG lipid
membrane for 20 h (data can be found in Fig. S3). There-
fore, the studies of these smaller species and their
membrane permeabilization may provide new, to our knowl-
edge, insights into the molecular mechanisms underlying
the failure of cellular homeostasis in AD.
Fast-forming amyloid (1–40) have recently also been
reported to develop during a short (~10 min) incubation of
50 nM peptide with SHSY5Y neuroblastoma cells (56).
As found in the current work, no oligomers were detected
in solution revealing that the cell membrane also greatly
facilitates the rate of oligomerization, and supports the
further growth of the oligomers because cell-bound oligo-
mers were found to be significantly larger than those formed
on the surface of the glass slide. It should be noted that the
rate of on-cell oligomerization was much higher than that
here reported, with oligomers appearing within minutes.
Whether this is due solely to intrinsic differences between
the model membrane and the much more complex cell
membrane or to differences in experimental conditions
(the cells were kept in growth medium, which contains a
variety of metal ions, nutrients, and proteins that are known
to facilitate oligomer formation) is of interest and is the
subject of current studies.CONCLUSIONS
Although the membrane-disruption by bound b-amyloid
oligomer hypothesis has been supported by recent evidence,
there is a lack of understanding of the underlying mecha-
nism at the molecular level. Here, we used single-molecule
studies to follow the interactions between b-amyloid (1–40)
and anionic bilayer lipid membrane, and the subsequentBiophysical Journal 103(7) 1500–1509
1508 Ding et al.oligomer formation. Our results lead us to conclude that the
interaction between b-amyloid (1–40) and anionic mem-
brane starts with an extremely tight binding of monomeric
peptide, and that further incubation leads to oligomer forma-
tion in the membrane. The sizes of the formed oligomers are
dependent on the concentration of b-amyloid (1–40) peptide
in solution. Specifically, at low nanomolar concentrations of
b-amyloid (1–40), a range that is of physiological signifi-
cance, a large fraction of the formed oligomers exist as
small species (trimer/tetramer), suggesting a possible mech-
anism for the origin of pore-forming oligomers. Single-
molecule imaging is uniquely suited to the identification
of early b-amyloid oligomers on biological membranes,
their evolution, and membrane interactions. The approaches
described in this work, when applied to live cell membranes,
should provide a more detailed understanding of the molec-
ular mechanism of AD.SUPPORTING MATERIAL
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